Preclinical evidence suggests that not only rhACE2 but also the exogenous administration of Ang-(1-7) peptide can improve severe clinical ARDS conditions such as low oxygenation and high inflammation status [113,114]. This evidence concerns the gene ANG and acute respiratory distress syndrome.